Report on cohort event monitoring (CEM) of Dolutegravir containing ART regimens in selected health facilities of Addis Ababa, Ethiopia

Abstract

Even though the introduction of DTG based ART has provided a potent treatment option for persons living with HIV, there is growing evidence from clinical settings that use of DTG can result in hyperglycemia, serious neurologic and neuropsychiatric side effects. Moreover, there is currently insufficient information regarding the safety of DTG-based combination regimen, including the types and frequency of suspected adverse drug events (ADEs) experienced and reported in Ethiopian population. Hence, the Ethiopian Food and Drug Authority (EFDA) conducted a Cohort Event Monitoring (CEM) on DTG based regimen in collaboration with stakeholders and partners among patients receiving ART service in selected health facilities of Addis Ababa.